NASD · Healthcare · Biotechnology · Canada
ProMIS Neurosciences Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
ProMIS Neurosciences develops antibody therapies and therapeutic vaccines targeting misfolded proteins in neurodegenerative and other diseases. The company utilizes its EpiSelect platform technology to identify disease-specific epitopes on toxic protein forms, enabling selective targeting without affecting healthy proteins. ProMIS' pipeline addresses conditions including Alzheimer's disease, multiple system atrophy, amyotrophic lateral sclerosis, and other neurological disorders.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the ProMIS Neurosciences Inc stock.
Not valued: We cannot value this company yet.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on PMN yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.